U.S. grants broader patent to Vidac Pharma’s oncology drug candidates, adding range of new indications including prostate and pancreatic cancer

• S. patent office widens patent to include broad range of new cancer indications including prostate, pancreatic, lung, cervical and colon cancer
• Vidac on track to meet new milestones underscoring the potential of its two drug candidates in wide range of tumors next year

London (UK),  December 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Today the company announces that the U.S. Patent and Trademark Office (USPTO) has widened a patent protecting the active compounds in its oncology drug candidates to include lymphomas that are metastases of prostate cancer, pancreatic cancer and a broad number of other indications and modes of administration.

“The indications that Vidac’s two drug candidates contain revolutionary potential on a wide range of tumors are growing, and the broadening of our U.S. patent is confirmation that we are on the right track.  , which we are keen to share with the medical community and investors as soon as we can,” said Prof Max Herzberg, CEO of Vidac Pharma.

The continuation in part patent also includes colon, cervical and lung cancer as new indications, underscoring the potential of Vidac’s drug candidates to form an entirely new class of cancer treatments. The company is developing two assets, VDA-1102, which is in mid-stage clinical studies to treat advanced actinic keratosis, and in Phase 2 for cutaneous T-cell lymphoma. Its more recent candidate, VDA-1275, has shown statistically significant efficacy as a monotherapy in animal studies, as well as synergistic effects in combination with two standard-of-care cancer treatments. VDA-1275 also triggered an immunologic response of its own, inducing anti-tumor macrophages and memory T-cells, and inhibiting tumor-promoting macrophages.

Both Vidac Pharma’s product candidates disrupt the interaction between the hexokinase 2 (HK2) isozyme and the voltage-dependent anion channels (VDACs) in mitochondria. Cancer cells overexpress HK2, which catalyzes the first step of the glucose metabolism, necessary to fuel tumor growth. HK2 blocks the channels, which prevents programmed cell death (apoptosis), supports cancer cell proliferation, and suppresses immune responses. The resulting high concentrations of lactate lead to an acidic and low-oxygen micro-environment in the cancer cells and the nearby tumor microenvironment, which fosters cancer growth. Clinical data for Vidac’s first-generation metabolic checkpoint modulator candidates have shown effects in halting cancer cell proliferation and restoring immune-sensitivity and apoptosis.

For more information please contact:

Max - is this correct to say? It’s based on what you told us about new results with CTCL and with VDA1275 in animals, which you will be announcing next year.

About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.

Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.